An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.

Abstract excerpt

INTRODUCTION: KRAS mutations are among the most common oncogenic alterations in colorectal cancer (CRC). These mutations play a central role in tumor initiation and progression through activation of the MAPK signaling pathway. For many years, KRAS was considered an undruggable target. However, recent advances have led to the development of allele-specific inhibitors and combination strategies that directly target...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Biomarkers, Tumor
• Share to Colorectal Neoplasms